MEDTIDE Executive Closed-Door Forum 2026 Concludes Successfully: Top-Level Dialogue Reshapes the Peptide Industry Landscape

Honored Milestone: Medtide Inc. Named in the "Top 20 Pharmaceutical CDMO Enterprises 2026"

Chinese Peptide Company, Subsidiary of Medtide Inc.: Tirzepatide API Successfully Secures US FDA DMF Filing, Fully Empowering the Global Weight Loss and Metabolism Arena

Good News | Medtide Inc.’s Subsidiary Chinese Peptide Company Sees Triptorelin Pamoate API Accepted for CDE Registration, Adding a New Product to Its Peptide Hormone Regulatory Portfolio